Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study

Acta Ophthalmologica

Volumn 88, Issue 1, 2010, Pages 12-19

  Uusitalo, Hannu ^a   Pillunat, Lutz E ^b   Ropo, Auli ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Santen Oy   (Finland)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Safety; Tafluprost

Indexed keywords

EYE DROPS; LATANOPROST; TAFLUPROST;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRY EYE; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYELASH DISCOLORATION; EYELASH THICKENING; EYELID EDEMA; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76149130033     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01862.x     Document Type: Article

References (35)

1. Alm A Stjernschantz J (1995 Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102 : 1743 1752.
2. Alm A Widengård I (2000 Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 78 : 71 76.
3. Alm A, Schoenfelder J McDermott J (2004 A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 122 : 957 965.
4. Alm A, Grierson I Shields MB (2008 Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 53 (Suppl. 1 S93 S105.
5. Baudouin C (2008 Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86 : 716 726.
6. Camras CB (1996 Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103 : 138 147.
7. Cox JA, Mollan SP, Bankart J Robinson R (2008 Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol 92 : 729 734.
8. Cracknell KP Grierson I (2009 Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects. Exp Eye Res 88 : 786 791.
9. Diestelhorst M Larsson LI (2006 A 12-Week, Randomized, double-masked, multicenter study of the fixed combination of Latanoprost and Timolol in the evening versus the individual components. Ophthalmology 113 : 70 76.
10. Egorov E Ropo A (2009 Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol 19 : 5 5.
11. European Glaucoma Society (2003 Terminology and guidelines for glaucoma, 2nd edn. Savona, Italy : Editrice DOGMA.
12. Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S Mills E (2009 Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol 3 : 447 456.
13. Feldman RM (2003 Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 19 : 23 35.
14. Goñi FJ (2005 Brimonidine/timolol fixed combination study group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 15 : 581 590.
15. Gordon MO Kass MA (1997 Ocular hypertension treatment study (OHTS) manual of procedures. Version 2.0. Washington, DC : National Technical Information Services.
16. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U Ropo A (2008 Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 242 : 14 19.
17. Hedman K, Watson PG Alm A (2002 The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 47 (Suppl. 1 S65 S76.
18. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A Zeyen T (2007 Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17 : 341 349.
19. Kass MA, Heuer DK, Higginbotham EJ et al. (2002 The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 : 701 713.
20. Lee CW, Buckley F, Costello S Kelly S (2008 A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. Curr Med Res Opin 24 : 2265 2270.
21. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L Komaroff E Early Manifest Glaucoma Trial Group (2003 Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121 : 48 56. (Pubitemid 36401765)
22. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y Hara H (2003 New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 26 : 1691 1695.
23. Parrish RK, Palmberg P Sheu WP XLT Study Group (2003 A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 : 688 703.
24. Reardon G, Schwartz GF Mozaffari E (2003 Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 25 : 1172 1185.
25. Stjernschantz JW, Albert DM, Hu DN, Drago F Wistrand PJ (2002 Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 47 (Suppl. 1 S162 S175.
26. Strohmaier K, Snyder E, DuBiner H Adamsons I (1998 The efficacy and safety of the Dorzolamide-Timolol combination verses the concomitant administration of its components. Ophthalmology 105 : 1936 1944.
27. Sutton A, Gilvarry A Ropo A (2007 A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 23 : 359 365.
28. Sutton A, Gouws P Ropo A (2008 Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 46 : 400 406.
29. Takagi Y, Nakajima T, Shimazaki A et al. (2004 Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78 : 767 776.
30. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7 (2006 The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 : 429 440.
31. Traverso CE, Papadia M, Ropo A, Mäkinen P Uusitalo H (2006 A pilot phase II study on the extent, duration of action and stability of the IOP lowering effect of tafluprost 0.0015%, a novel prostaglandin analogue, as compared to latanoprost 0.005%. Acta Ophthalmol Scand 84 : 36 37.
32. Uusitalo H, Kaarniranta K Ropo A (2008 Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf) 242 : 7 13.
33. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F Prins MH (2005 Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 : 1177 1185.
34. Watson PG (1998 Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 105 : 82 87.
35. Watson P Stjernschantz J (1996 A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103 : 126 137.